This study highlights the importance of monitoring viral capsid protein charge distribution in AAV gene therapy vectors to ensure product quality. Using imaged capillary isoelectric focusing (icIEF), we developed a method to detect charge heterogeneity due to post-translational modifications, such as deamidation, which can reduce vector potency.
Resources
May 03, 2024
Scientific Poster: Development of an Analytical Method For AAV Capsid Protein For Use in Stability Studies
Explore more
Insights
Viralgen Vector Core and Elpida Therapeutics partner to manufacture gene therapy medicines for anticipated Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) clinical trials Trial participants with Spastic Paraplegia 50...
READ MORE
September 29, 2023

Insights
Last week, we participated in the ASGCT 26th Annual Meeting, which was held in Los Angeles. We are grateful for a successful meeting at ASGCT and would like to thank all our booth visitors, customers who took time out to meet with the team, and...
READ MORE
May 24, 2023

Insights
ASGCT 26th Annual Meeting starts in a few days. This year, it will be held in Los Angeles from May 16 to 20, and Viralgen will be present at booth 123. The American Society of Gene and Cell Therapy's (ASGCT) Annual Meeting is the premier event for...
READ MORE
April 14, 2023